Stoke Therapeutics STOK
$26.81 −$0.12 (-0.45%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.40 +2.20%
Open$26.39
Prev close$26.93
Day range$25.94 – $27.78
Volume615.8K
Market cap$1.75B
P/E (TTM)–
Dividend yield–
STOK Stock News
Headlines matching Stoke Therapeutics or the STOK ticker, most recent first.
- A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $40 to $60
- Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE) Positive
- Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
- J.P. Morgan Upgrades Stoke Therapeutics(STOK.US) to Buy Rating, Raises Target Price to $40 Positive
- CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $58
- Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40
- Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44
- Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK), Genelux Corp. (GNLX) and Celldex (CLDX)
- A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60
- TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
- Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60
- BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39
- H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50
- CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $60 Positive
- Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $38
No comments yet — be the first to weigh in on STOK.
Sign in to join the discussion.